Sanofi will buy Dynavax Technologies for around $2.2 billion, the French drugmaker announced Wednesday. The deal hands Sanofi an approved hepatitis B vaccine in the U.S. and a promising experimental shingles shot that could shake up the market.
It’s been a busy year for Sanofi. The pharmaceutical giant is on a shopping spree, snapping up smaller biotech companies left and right. This latest acquisition shows how serious the company is about expanding its vaccine portfolio beyond its cash cow, the blockbuster asthma drug Dupixent. That medication has been printing money for Sanofi, but executives know you can’t ride one product forever.
The numbers tell the story. Sanofi will pay $15.50 per share in cash for Dynavax. That’s a 39% premium over the Tuesday closing price—a hefty markup that shows Sanofi really wants this deal. Looking at the three-month volume-weighted average, the premium jumps to 46%. Investors holding Dynavax shares woke up to good news.
This isn’t Sanofi’s first rodeo this year. Back in July, the French pharmaceutical giant bought British private biotech firm ViceBio for $1.5 billion. That’s a string of acquisitions worth billions of dollars in just months. Wall Street analysts say Sanofi looks serious about reshaping its business before patent cliffs start hitting its biggest money-makers.
So what exactly is Sanofi getting for its 2.2 billion dollars (about 1.9 billion euros)? The crown jewel is Dynavax’s hepatitis B vaccine, already approved and selling in American markets. That gives immediate revenue. But there’s more.
The real prize might be sitting in Dynavax’s lab. Their experimental shingles vaccine is still in early-stage testing, but August data turned heads across the pharmaceutical industry. Dynavax said the candidate generated a similar immune response to GSK’s blockbuster shot Shingrix while showing a better safety profile in an early-to-mid-stage study. That’s huge. Shingrix dominates the shingles market and brings in billions for GSK every year.
If Dynavax’s shingles candidate pans out, Sanofi could grab a piece of that massive pie. The vaccine market is cutthroat competitive. Big players fight over every percentage point of market share. Sanofi knows this battlefield well.
The deal won’t close tomorrow. Sanofi expected to complete the acquisition in the first quarter of 2026. That gives regulators time to review everything. The company plans to use available cash for the purchase, which tells you Sanofi’s balance sheet is healthy. Management added the transaction would not affect its 2025 financial outlook. Translation: they’ve got the money and the deal won’t mess up their earnings forecasts.
But Wednesday brought mixed news for Sanofi. Separately, while announcing the Dynavax purchase, the company revealed the U.S. Food and Drug Administration (FDA) declined to approve its experimental drug tolebrutinib. That medication was meant to treat patients with a form of multiple sclerosis. The rejection stings, but it explains why drugmakers like Sanofi pursue acquisitions. Developing drugs internally is risky. Buying companies with approved products is safer.
This pattern of buying rather than building reflects broader pharmaceutical industry trends. Why gamble on experimental candidates when you can acquire approved vaccines and drugs that already generate revenue? Sanofi’s strategy makes business sense. Dupixent won’t stay on top forever. Patent protections eventually expire. Competition always catches up.
The premium pay structure—that 39% markup over Tuesday’s price—signals strong confidence. Sanofi sees real value in Dynavax Technologies. The vaccines business keeps growing, especially with aging populations worldwide needing shingles protection and hepatitis B prevention.
Market watchers will track how Sanofi integrates Dynavax operations into its existing structure. Merging companies sounds simple on paper. Reality is messier. Different corporate cultures clash. Systems don’t always mesh smoothly. But Sanofi has experience with acquisitions—this isn’t their first merger rodeo.
The deal positions Sanofi differently for the next decade. Diversify growth now or face problems later. That seems to be management’s thinking. With the FDA maintaining tough approval standards and dozens of biotech firms chasing the same markets, speed matters. Acquisitions deliver faster than internal research and development cycles that stretch over decades.
For Dynavax shareholders, the representing 46% volume-weighted average premium means payday. For Sanofi investors, it means watching billions flow into vaccines rather than returning as dividends. The pharmaceutical company is betting big that this purchase pays off long-term. Time will tell if Sanofi got a bargain or overpaid.
